A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
A Phase II Study of Velcade® (Bortezomib) in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Villejuif, France, 94800
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically documented, inoperable, unresectable, incurable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) non-small cell lung cancer. (Note: Histology is the preferred method of diagnosis. However, in case only cytology is available, specimens from brushing, washing or needle aspiration etc. are acceptable for diagnosis. Sputum cytology alone is not acceptable)
- No prior chemotherapy or therapy with systemic anti-tumour therapy (e.g., monoclonal antibody therapy). Prior surgery and/or localized irradiation (palliative RT or curative RT) is permitted. Pre operative or post operative anti neo-plastic therapy is allowed if ended more than 2 years ago
- No prior exposure to agents directed at the HER axis (e.g. EGFR TK Inhibitors, Herceptin)
- Measurable disease as defined by RECIST criteria (attachment 1)
- Age 18 or greater
- ECOG performance status of 0 - 2 (attachment 2)
- Life expectancy of at least 12 weeks
- At least 4 weeks since any prior surgery or radiotherapy. Patients who, in the opinion of the investigator, have fully recovered from surgery in less than 4 weeks may also be considered for the study. Patients must have recovered (CTC < 1) from acute toxicities of any previous therapy
- Granulocyte count > 1.5 x 109/L, platelet count > 100 x 109/L and hemoglobin >8.0 g/dL
- Serum bilirubin must be < 1.5 upper limit of normal (ULN) or ≤ 5 times ULN in patients with liver metastases. SGOT (AST) and SGPT (ALT) must be < 3 x ULN.
- Serum creatinine < 1.5 ULN or creatinine clearance > 60 ml/min
- Normal serum calcium
- Able to comply with study and follow-up procedures
- For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before registration starting therapy
- Patients with reproductive potential must use effective contraception
- Written (signed) Informed Consent to participate in the study.
Exclusion Criteria:
- Any unstable systemic disease [including active infection, uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 3, NYHA Classification of Cardiac Disease), myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease] or Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
- Patients are excluded if they have brain metastasis or spinal cord compression that is newly diagnosed and/or has not yet been definitively treated with surgery and/or radiation; previously diagnosed and treated CNS metastases or spinal cord compression with evidence of stable disease (clinically stable imaging) for at least 2 months is permitted
- Any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the study drug or that might affect the interpretation of the results or render the subject at high risk from treatment complications
- Nursing mothers
- Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
- Neuropathy ³ Grade 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Efficacy of VELCADE as determined by the rate of no progression at 6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Duration of objective response
|
|
Progression-free survival (PFS)
|
|
Overall survival (OS)
|
|
Efficacy of VELCADE as determined by
|
|
Objective response rate (incidence of CR and PR)
|
|
Disease control rate (CR, PR and stabilization)
|
|
Duration of disease control
|
|
Safety of VELCADE
|
|
Rate of doublet therapy in second line
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jean-Charles SORIA, MD, PhD, Gustave Roussy, Cancer Campus, Grand Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Inorganic Chemicals
- Boronic Acids
- Acids, Noncarboxylic
- Acids
- Boron Compounds
- Pyrazines
- Bortezomib
Other Study ID Numbers
Other Study ID Numbers
- VELCADE
- CSET 1192
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.